

Section II (Amendments to the Claims)

Please amend claims 1-3, 5, 15, 19(a), and add new claim 22, as set out in the listing of claims 1-22 below.

1. (Currently Amended) A F_V antibody construct having variable domains ~~binding sites~~ for an CD16 ~~receptor~~ and ~~[[a]] CD30 surface-protein~~ but no constant domains, and inducing a regression of Hodgkin's disease *in vivo*.
2. (Currently Amended) The F_V antibody construct according to claim 1, wherein the CD16 ~~receptor~~ is derived from natural killer cells (NK cells).
3. (Currently Amended) The F_V antibody construct according to claim 1, wherein the CD30 ~~surface-protein~~ is derived from a member selected from the group consisting of: Hodgkin's disease cells or Reed-Sternberg cells.
4. (Previously presented) The F_V antibody construct according to claim 1, wherein one binding site is present each.
5. (Currently amended) The F_V antibody construct according to claim 4, encoded by the expression vector pKID16-30 (DSEM 12960).
6. (Previously presented) The F_V antibody construct according to claim 1, wherein two binding sites are present for each.
7. (Previously presented) An expression vector, coding for the F_V antibody construct according to claim 1.
8. (Previously presented) The expression vector according to claim 7, which is pKID16-30 (DSM 12960).
9. (Previously presented) A transformant, containing the expression vector according to claim 7.

10. (Previously presented) A method of producing the F_v antibody construct according to claim 1, comprising culturing the transformant according to claim 9 under suitable conditions.
11. (Previously presented) A kit comprising:
 - (a) an F_v antibody construct having binding sites for an CD16 receptor and a CD30 surface protein
and/or
 - (b) an expression vector coding for said F_v antibody construct, and
 - (c) at least one auxiliary substance selected from the group consisting of buffers, solvents, carriers, controls and markers,wherein one or more representatives of the individual components may be present.
12. (Previously presented) A method for lysis of cells expressing CD30 surface proteins, said method comprising contacting said cells with an F_v antibody construct having binding sites for an CD16 receptor and a CD30 surface protein.
13. (Previously presented) A method according to claim 12, wherein the cells are tumor cells.
14. (Previously presented) A method according to claim 13, wherein the tumor cells are selected from the group consisting of: Hodgkin's disease cells or Reed-Sternberg cells.
15. (Currently Amended) The F_v antibody construct according to claim 2, wherein the CD30 ~~surface protein~~ is derived from a member selected from the group consisting of: Hodgkin's disease cells ~~or~~ and Reed-Sternberg cells.
16. (Previously presented) An expression vector, coding for the F_v antibody construct according to claim 15.
17. (Currently amended) A method for lysis of cells expressing CD30 surface proteins, said method comprising contacting said cells with an F_v antibody construct having binding sites for an CD16 receptor and a CD30 surface protein, wherein the CD16 receptor is derived from natural killer cells (NK cells), and wherein the CD30 surface protein is derived from a member selected from the group consisting of: Hodgkin's disease cells or Reed-Sternberg cells.

18. (Previously presented) A transformant, containing the expression vector according to claim 8.
19. (Currently amended) The F_V construct of claim 1, wherein said F_V antibody construct comprises elements (a) and (b) joined via a peptide linker:
- (a) a VH domain of an anti-CD16 antibody and a VL domain of an anti-CD30 antibody, the domains being joined by a peptide linker; and
 - (b) a VH domain of an anti-CD30 antibody and a VL domain of an anti-CD16 antibody, the domains joined by a peptide linker.
20. (Previously presented) A method of treatment of a tumor comprising the step of administering the F_V antibody construct according to claim 1.
21. (Previously presented) The method of claim 20, wherein the treatment comprises the lysis of Hodgkin's disease or Reed-Sternberg cells.
22. (New) The F_V antibody construct according to claim 1, wherein said F_V antibody is capable of inducing a more intense lysis of CD30 carrying cells *in vitro* than bimAbHRS-3/A9 (DSM ACC2142).